ARA-290 and Erythropoietin-Derived Peptides: Why Receptor Names Need Evidence Labels
ARA-290 is an erythropoietin-derived peptide studied in models that often use the labels EPOR/CD131, beta-common receptor, or innate repair receptor. Those names should be treated as evidence labels, not as interchangeable proof of one directly observed receptor structure. A careful reading separates peptide identity, receptor-component expression, functional signaling, direct binding, and the model in which each observation was made.
What is ARA-290?
ARA-290, also called cibinetide in parts of the literature, is a short peptide derived from the three-dimensional surface of erythropoietin rather than from the hormone's full linear sequence. The original peptide-design work described tissue-protective peptides intended to reproduce selected non-erythropoietic signals without reproducing erythropoiesis. That derivation explains why ARA-290 papers discuss erythropoietin-receptor biology, but it does not by itself establish which receptor complex binds the peptide in every experimental system. Brines et al. (2008)
For any material record, the first question is still identity: which sequence, terminal form, counterion, and preparation did the study use? A receptor label cannot authenticate a vial, and an analytical identity result cannot prove a receptor mechanism. These are separate evidence tracks.
Why does “EPOR/CD131” need a qualifier?
A receptor name can compress several different observations. A study may report that two receptor components are expressed, that a downstream endpoint changes after adding a peptide, that genetic or antibody perturbation changes the response, or that purified proteins bind directly. These observations do not carry the same mechanistic weight.
Bohr and colleagues studied mouse mesenchymal-derived cell phenotypes under defined stress conditions. The paper measured outcomes that included CD131 surface expression, cell-stress responses, cytokine secretion, phosphorylation, and transcription-factor behavior. The authors interpreted the findings within an EPO-R/CD131 signaling model. This is useful functional evidence in those cell systems and conditions. It is not the same experiment as directly resolving the composition, stoichiometry, or structure of a ligand-bound receptor complex. Bohr et al. (2015)
A receptor-evidence table
| Claim in a paper | Evidence that can support it | What the evidence does not establish alone |
|---|---|---|
| The test material was ARA-290 | Stated sequence, synthesis record, mass and orthogonal identity data | Receptor architecture or signaling |
| EPOR and CD131 were present in the model | Transcript, protein, or surface-expression measurements | Direct ligand binding to a heteromer |
| ARA-290 changed a cellular endpoint | Matched controls, defined stressor, time point, and endpoint assay | Which physical receptor assembly caused the change |
| A receptor component contributed to a response | Genetic loss, knockdown, blocking reagent, or rescue experiment | Direct contact between the peptide and every named component |
| Two purified receptor regions associate | Reproducible biophysical interaction under stated conditions | Behavior in every membrane and cell context |
The safest summary therefore names both the observation and its level: “functional signaling evidence in stressed mesenchymal-derived cells,” for example, rather than “proof of the ARA-290 receptor.”
What did the direct-interaction study test?
Socolovsky and colleagues examined extracellular regions of the erythropoietin receptor and beta-common receptor using biophysical methods. Under the reported conditions, the study did not detect a specific association promoted by erythropoietin or ARA-290. That result directly challenges a simple, stable extracellular heteroreceptor model under those assay conditions. It does not erase every cell-based signaling observation, because purified-protein interaction assays and intact-cell functional assays answer different questions. Socolovsky et al. (2018)
This is a productive disagreement, not a reason to choose one paper and ignore the other. The functional study asks whether defined cells change measurable responses after a perturbation. The biophysical study asks whether specified purified receptor regions form a detectable association. A responsible review keeps both findings visible and states that the physical receptor-complex model remains unresolved.
How to compare two ARA-290 papers
Start with the material definition, then record the biological system and evidence type. A compact comparison sheet should include:
- the exact peptide name, sequence or cited preparation;
- species, cell type, tissue, or purified proteins;
- receptor-component expression evidence;
- peptide concentration and exposure window as experimental descriptors, without turning them into use guidance;
- controls, including inactive analogues or vehicle controls where reported;
- the measured endpoint and the time at which it was read;
- whether the conclusion is functional, genetic, biochemical, or structural;
- conflicts of interest or sponsor relationships reported by the paper.
This method prevents a downstream stress-response result from being retold as a direct binding measurement. It also prevents a negative purified-protein result from being stretched into proof that no context-dependent signaling relationship can exist.
For a repeatable way to capture these fields, use the Research-Peptide Literature Matrix. When mass alone cannot settle a peptide identity question, the Peptide Stereochemistry guide explains the missing dimensions. The Research Peptide Documentation Workflow keeps literature evidence separate from a supplied lot record.
What this means for a catalog record
A catalog page can identify a supplied material and connect it to available documentation. It should not inherit the biological outcomes of a cited paper. Likewise, placement in Research Compounds is catalog organization, not receptor evidence.
A product specification, lot document, and scientific paper answer different questions. Product documentation can describe the supplied material and reported testing. The paper describes its own material and protocol. A defensible connection requires an explicit identity match; a shared name is not enough.
Research limitations
The receptor literature includes model-dependent functional findings and disputed direct-interaction evidence. Cell stressors, receptor expression, membrane context, controls, and readouts differ across studies. None of these papers establishes human benefit, dosing, safety, or the performance of a catalog product. The conclusions here are limited to how receptor claims should be classified and compared.
Frequently asked questions
Is EPOR/CD131 a confirmed physical receptor structure for ARA-290?
The literature does not justify presenting that architecture as settled. Some cell studies interpret functional responses through an EPOR/CD131 model, while direct biophysical work did not detect the proposed association under its tested conditions.
Does a signaling response prove direct binding?
No. A downstream response can support functional involvement, but direct binding requires an assay designed to measure physical interaction, along with appropriate controls and reproducibility.
What is the most important field when comparing ARA-290 studies?
There is no single field. Compare the peptide definition, model, receptor evidence, perturbation, controls, endpoint, and claim type together.
Can a paper verify the identity or quality of a product lot?
No. A paper supports claims about its reported research material. Lot identity and reported testing require documentation tied to that specific lot.